Ann: Brazil Distribution Agreement signed for MGC Pharma Products, page-31

As I said earlier, there is no point having distributors if we do not have as much production. Can someone please present a back of the envelope calculation to show how much CBD we are getting out of the existing cultivation in Europe? And perhaps what dosage it translates to for the patients?

Another point is that I am not so sure about the value in supplying directly to the patient. I thought it would be more cost effective and more streamlined for MXC to have bulk or large number delivery to the distributor and they can do what they like to do with it (bound by their medico/legal obligations of course). We are a pharma company not running a pharmacy! There will be logistic issues that may not be within MXC's expertise to deal with and which divert our focus.